Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder

A 12-week prospective, open-label, randomized, parallel-group trial

Changsu Han, Chi Un Pae, Bun Hee Lee, Young-Hoon Ko, Prakash S. Masand, Ashwin A. Patkar, Sook Haeng Joe, In Kwa Jung

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: We set out to compare the efficacy and tolerability of mirtazapine versus venlafaxine in patients with undifferentiated somatoform disorder (USD) using the Patient Health Questionnaire-15 (PHQ-15). Methods: This was a 12-week prospective, open-label, randomized, parallel-group trial. The trial consisted of six visits that included baseline and weeks 1, 2, 4, 8 and 12. The primary effectiveness measure was the mean change in PHQ-15 total score from baseline to the end of treatment. Secondary effectiveness measures included the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ) from baseline to the end of treatment. Ninety-five subjects were randomized to either mirtazapine (n = 50) or venlafaxine (n = 45); 71 subjects completed the study (mirtazapine: n = 39/50 [78%]; venlafaxine: n = 32/45 [71%]). Results: The mean total score on the PHQ-15 decreased by 34.7% (-8.4, p < 0.0001) from baseline to endpoint in the mirtazapine group and by 26.6% (-6.1, p < 0.0001) in the venlafaxine group. A marginally significant between-group difference was observed for the mean change in total score on the PHQ-15 from baseline to endpoint (F = 4.126, p = 0.046). The mean total scores on the GHQ-12 and BDI from baseline to endpoint decreased by -4.9 (29.4%, p < 0.0001) and -13.5 (55.9%, p < 0.0001), respectively, in the mirtazapine group, and by -4.3 (26.2%, p = 0.001) and -9.02 (46.0%, p < 0.0001), respectively, in the venlafaxine group. No between-group difference was observed for the mean changes in total scores on the secondary effectiveness measures from baseline to endpoint. Both treatments were well tolerated. Conclusion: Our findings suggest that both mirtazapine and venlafaxine may be effective and well tolerated in the treatment of patients with USD. Double-blind, placebo-controlled and/or head-to-head comparison studies are required to allow definite conclusions to be drawn.

Original languageEnglish
Pages (from-to)251-261
Number of pages11
JournalClinical Drug Investigation
Volume28
Issue number4
DOIs
Publication statusPublished - 2008 Mar 27

Fingerprint

Somatoform Disorders
compound A 12
Health
Therapeutics
Depression
Equipment and Supplies
Surveys and Questionnaires
mirtazapine
Venlafaxine Hydrochloride
Placebos

Keywords

  • Mirtazapine, therapeutic use
  • Somatoform disorders
  • Venlafaxine, therapeutic use

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder : A 12-week prospective, open-label, randomized, parallel-group trial. / Han, Changsu; Pae, Chi Un; Lee, Bun Hee; Ko, Young-Hoon; Masand, Prakash S.; Patkar, Ashwin A.; Joe, Sook Haeng; Jung, In Kwa.

In: Clinical Drug Investigation, Vol. 28, No. 4, 27.03.2008, p. 251-261.

Research output: Contribution to journalArticle

Han, Changsu ; Pae, Chi Un ; Lee, Bun Hee ; Ko, Young-Hoon ; Masand, Prakash S. ; Patkar, Ashwin A. ; Joe, Sook Haeng ; Jung, In Kwa. / Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder : A 12-week prospective, open-label, randomized, parallel-group trial. In: Clinical Drug Investigation. 2008 ; Vol. 28, No. 4. pp. 251-261.
@article{df7d314165f54ed384a3bb51c67bd1e1,
title = "Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: A 12-week prospective, open-label, randomized, parallel-group trial",
abstract = "Objective: We set out to compare the efficacy and tolerability of mirtazapine versus venlafaxine in patients with undifferentiated somatoform disorder (USD) using the Patient Health Questionnaire-15 (PHQ-15). Methods: This was a 12-week prospective, open-label, randomized, parallel-group trial. The trial consisted of six visits that included baseline and weeks 1, 2, 4, 8 and 12. The primary effectiveness measure was the mean change in PHQ-15 total score from baseline to the end of treatment. Secondary effectiveness measures included the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ) from baseline to the end of treatment. Ninety-five subjects were randomized to either mirtazapine (n = 50) or venlafaxine (n = 45); 71 subjects completed the study (mirtazapine: n = 39/50 [78{\%}]; venlafaxine: n = 32/45 [71{\%}]). Results: The mean total score on the PHQ-15 decreased by 34.7{\%} (-8.4, p < 0.0001) from baseline to endpoint in the mirtazapine group and by 26.6{\%} (-6.1, p < 0.0001) in the venlafaxine group. A marginally significant between-group difference was observed for the mean change in total score on the PHQ-15 from baseline to endpoint (F = 4.126, p = 0.046). The mean total scores on the GHQ-12 and BDI from baseline to endpoint decreased by -4.9 (29.4{\%}, p < 0.0001) and -13.5 (55.9{\%}, p < 0.0001), respectively, in the mirtazapine group, and by -4.3 (26.2{\%}, p = 0.001) and -9.02 (46.0{\%}, p < 0.0001), respectively, in the venlafaxine group. No between-group difference was observed for the mean changes in total scores on the secondary effectiveness measures from baseline to endpoint. Both treatments were well tolerated. Conclusion: Our findings suggest that both mirtazapine and venlafaxine may be effective and well tolerated in the treatment of patients with USD. Double-blind, placebo-controlled and/or head-to-head comparison studies are required to allow definite conclusions to be drawn.",
keywords = "Mirtazapine, therapeutic use, Somatoform disorders, Venlafaxine, therapeutic use",
author = "Changsu Han and Pae, {Chi Un} and Lee, {Bun Hee} and Young-Hoon Ko and Masand, {Prakash S.} and Patkar, {Ashwin A.} and Joe, {Sook Haeng} and Jung, {In Kwa}",
year = "2008",
month = "3",
day = "27",
doi = "10.2165/00044011-200828040-00006",
language = "English",
volume = "28",
pages = "251--261",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder

T2 - A 12-week prospective, open-label, randomized, parallel-group trial

AU - Han, Changsu

AU - Pae, Chi Un

AU - Lee, Bun Hee

AU - Ko, Young-Hoon

AU - Masand, Prakash S.

AU - Patkar, Ashwin A.

AU - Joe, Sook Haeng

AU - Jung, In Kwa

PY - 2008/3/27

Y1 - 2008/3/27

N2 - Objective: We set out to compare the efficacy and tolerability of mirtazapine versus venlafaxine in patients with undifferentiated somatoform disorder (USD) using the Patient Health Questionnaire-15 (PHQ-15). Methods: This was a 12-week prospective, open-label, randomized, parallel-group trial. The trial consisted of six visits that included baseline and weeks 1, 2, 4, 8 and 12. The primary effectiveness measure was the mean change in PHQ-15 total score from baseline to the end of treatment. Secondary effectiveness measures included the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ) from baseline to the end of treatment. Ninety-five subjects were randomized to either mirtazapine (n = 50) or venlafaxine (n = 45); 71 subjects completed the study (mirtazapine: n = 39/50 [78%]; venlafaxine: n = 32/45 [71%]). Results: The mean total score on the PHQ-15 decreased by 34.7% (-8.4, p < 0.0001) from baseline to endpoint in the mirtazapine group and by 26.6% (-6.1, p < 0.0001) in the venlafaxine group. A marginally significant between-group difference was observed for the mean change in total score on the PHQ-15 from baseline to endpoint (F = 4.126, p = 0.046). The mean total scores on the GHQ-12 and BDI from baseline to endpoint decreased by -4.9 (29.4%, p < 0.0001) and -13.5 (55.9%, p < 0.0001), respectively, in the mirtazapine group, and by -4.3 (26.2%, p = 0.001) and -9.02 (46.0%, p < 0.0001), respectively, in the venlafaxine group. No between-group difference was observed for the mean changes in total scores on the secondary effectiveness measures from baseline to endpoint. Both treatments were well tolerated. Conclusion: Our findings suggest that both mirtazapine and venlafaxine may be effective and well tolerated in the treatment of patients with USD. Double-blind, placebo-controlled and/or head-to-head comparison studies are required to allow definite conclusions to be drawn.

AB - Objective: We set out to compare the efficacy and tolerability of mirtazapine versus venlafaxine in patients with undifferentiated somatoform disorder (USD) using the Patient Health Questionnaire-15 (PHQ-15). Methods: This was a 12-week prospective, open-label, randomized, parallel-group trial. The trial consisted of six visits that included baseline and weeks 1, 2, 4, 8 and 12. The primary effectiveness measure was the mean change in PHQ-15 total score from baseline to the end of treatment. Secondary effectiveness measures included the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ) from baseline to the end of treatment. Ninety-five subjects were randomized to either mirtazapine (n = 50) or venlafaxine (n = 45); 71 subjects completed the study (mirtazapine: n = 39/50 [78%]; venlafaxine: n = 32/45 [71%]). Results: The mean total score on the PHQ-15 decreased by 34.7% (-8.4, p < 0.0001) from baseline to endpoint in the mirtazapine group and by 26.6% (-6.1, p < 0.0001) in the venlafaxine group. A marginally significant between-group difference was observed for the mean change in total score on the PHQ-15 from baseline to endpoint (F = 4.126, p = 0.046). The mean total scores on the GHQ-12 and BDI from baseline to endpoint decreased by -4.9 (29.4%, p < 0.0001) and -13.5 (55.9%, p < 0.0001), respectively, in the mirtazapine group, and by -4.3 (26.2%, p = 0.001) and -9.02 (46.0%, p < 0.0001), respectively, in the venlafaxine group. No between-group difference was observed for the mean changes in total scores on the secondary effectiveness measures from baseline to endpoint. Both treatments were well tolerated. Conclusion: Our findings suggest that both mirtazapine and venlafaxine may be effective and well tolerated in the treatment of patients with USD. Double-blind, placebo-controlled and/or head-to-head comparison studies are required to allow definite conclusions to be drawn.

KW - Mirtazapine, therapeutic use

KW - Somatoform disorders

KW - Venlafaxine, therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=40949123518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949123518&partnerID=8YFLogxK

U2 - 10.2165/00044011-200828040-00006

DO - 10.2165/00044011-200828040-00006

M3 - Article

VL - 28

SP - 251

EP - 261

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 4

ER -